These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769 [TBL] [Abstract][Full Text] [Related]
10. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates. Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain. Poveda JL; Trillo JL; Rubio-Terrés C; Rubio-Rodríguez D; Polanco A; Torres C Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):295-303. PubMed ID: 31220959 [TBL] [Abstract][Full Text] [Related]
12. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]. Meuth SG; Ruck T; Aktas O; Hartung HP Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912 [TBL] [Abstract][Full Text] [Related]
13. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis. Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518 [TBL] [Abstract][Full Text] [Related]
14. [Recommendations for the use of cladribine tablets in recurring multiple sclerosis]. Oreja-Guevara C; García-Merino JA; Saiz A; Rodríguez-Antigüedad A; Álvarez-Cermeño JC; Estrada-Pérez V; Izquierdo G; Fernández O Rev Neurol; 2019 Dec; 69(s02):1-9. PubMed ID: 31933293 [TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon. Matni M; Yamout B; Koussa S; Khamis C; Fleifel L; Sharifi S; Mohamed O Mult Scler Relat Disord; 2022 Nov; 67():104169. PubMed ID: 36150262 [TBL] [Abstract][Full Text] [Related]
16. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. Rieckmann P; Centonze D; Giovannoni G; Hua LH; Oreja-Guevara C; Selchen D; Sørensen PS; Vermersch P; Wiendl H; Salloukh H; Yamout B Neurodegener Dis Manag; 2023 Feb; 13(1):5-13. PubMed ID: 36278394 [TBL] [Abstract][Full Text] [Related]
17. Efficiency Model of Cladribine Tablets Versus Infusion-Based Disease-Modifying Drugs for Patients with Relapsing-Remitting Multiple Sclerosis. Tafazzoli A; Chavan A; Harty G; Moller J; Wong SL Adv Ther; 2020 Sep; 37(9):3791-3806. PubMed ID: 32647909 [TBL] [Abstract][Full Text] [Related]
18. Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers. Habek M; Drulovic J; Brecl Jakob G; Barbov I; Radulovic L; Rajda C; Rejdak K; Turčáni P Neurol Ther; 2023 Feb; 12(1):25-37. PubMed ID: 36394714 [TBL] [Abstract][Full Text] [Related]
19. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971 [TBL] [Abstract][Full Text] [Related]
20. Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know. AlJumah M; Alkhawajah MM; Qureshi S; Al-Thubaiti I; Ayoub O; Bohlega SA; Bushnag A; Cupler E; Daif A; El Boghdady A; Hassan A; Al Malik Y; Saeedi J; Al-Shamrany F; Shosha E; Rieckmann P Neurol Ther; 2020 Jun; 9(1):11-23. PubMed ID: 32056129 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]